TL;DR
This study investigated the in vitro synergy between the antifungal amphotericin B and the antibiotic colistin against a range of fungi causing invasive infections. While the combination showed promising synergistic effects against Candida species, particularly C. auris, it was largely indifferent against Aspergillus and Rhizopus species, suggesting a targeted approach for this drug combination.
What Problem Does This Paper Address?
Invasive fungal infections pose a significant threat, especially to immunocompromised individuals, with high mortality rates. The limited arsenal of effective antifungal drugs, coupled with emerging resistance, necessitates the exploration of combination therapies. Amphotericin B is a broad-spectrum antifungal, but its use is associated with toxicity. Colistin, an antibiotic primarily used against Gram-negative bacteria, has shown some antifungal activity and has been explored in combination with other antifungals. This paper addresses the need to understand the potential synergistic or antagonistic interactions between amphotericin B and colistin across a diverse range of clinically relevant fungal pathogens, including those frequently implicated in severe infections like those seen in COVID-19 patients.
Methods
The researchers employed a standard microdilution checkerboard technique to assess the in vitro interactions between amphotericin B and colistin. This method involves testing various concentrations of each drug in combination against fungal isolates. To interpret the results, two primary methods were used:
- Fractional Inhibitory Concentration Index (FICI): This method, based on the Loewe additivity model, calculates an index to determine if the combination is synergistic (FICI ≤ 0.5), indifferent (0.5 < FICI ≤ 4), or antagonistic (FICI > 4). Different inhibition endpoints (50% and 90% growth inhibition) were used to capture interactions at both MIC and sub-MIC levels.
- Response Surface Analysis (RSA): This approach, based on the Bliss independence model, is independent of specific MIC endpoints. It compares the observed drug effects to the expected effects if the drugs acted independently, allowing for a more nuanced assessment of synergy and antagonism.
The study also utilized quality control reference strains to ensure the reliability of the experiments.
Datasets
The study utilized a collection of 86 fungal strains, comprising:
- 47 Candida species: Including C. albicans, C. auris, C. glabrata, C. kefyr, C. krusei, C. parapsilosis, and C. tropicalis.
- 29 Aspergillus species: Including A. flavus, A. fumigatus, A. nidulans, A. niger, and A. terreus.
- 10 Rhizopus species: Including R. arrhizus, R. delemar, and R. microsporus.
These strains were primarily clinical isolates, with some obtained from culture collections. The study did not introduce new benchmark datasets but rather evaluated the combination against well-characterized fungal species relevant to human infections.
Key Insights and Ideas
- Colistin's potential as an antifungal adjuvant: The study highlights that colistin, primarily an antibiotic, can exhibit synergistic effects with an antifungal like amphotericin B, particularly against certain Candida species. This suggests that drugs targeting bacterial membranes might have broader applications in antifungal therapy.
- Species-specific interactions: The effectiveness of the amphotericin B-colistin combination is highly dependent on the fungal species. This underscores the need for targeted approaches rather than a one-size-fits-all strategy in antifungal combination therapy.
- Methodological nuances in synergy assessment: The discrepancy in results between FICI and RSA, especially for C. tropicalis and C. auris, emphasizes the importance of using multiple interpretation methods and considering different inhibition endpoints. The FICI's sensitivity to weak interactions and its definition of antagonism were questioned.
- Potential for overcoming resistance: While not explicitly tested for resistance mechanisms in this study, synergistic interactions can be a strategy to overcome existing antifungal resistance or to reduce the emergence of new resistance.
Key Results
- Synergy against Candida species:
- Against common Candida species (excluding C. auris), the combination was synergistic for 75% of strains by FICI and 66% by RSA.
- For C. auris, RSA showed synergy in 73% of strains, while FICI indicated synergy in 33%.
- Interestingly, for C. tropicalis, FICI showed antagonism in some isolates, but this was not confirmed by RSA, suggesting a complex interaction.
- Indifference against Aspergillus and Rhizopus: The combination exhibited indifferent interactions against all tested Aspergillus and Rhizopus species.
- MIC ranges: Amphotericin B MICs for Candida species ranged from 0.25 to 0.5 µg/mL, while colistin MICs were generally high (>64 µg/mL), indicating limited intrinsic activity against most Candida species. For Aspergillus and Rhizopus, amphotericin B MICs were also in a similar range, with colistin showing minimal activity.
Limitations and Future Work
- In vitro vs. In vivo: The study is limited to in vitro experiments. The authors acknowledge that animal experiments are required to confirm the observed interactions, particularly for C. tropicalis.
- Toxicity concerns: Combining two nephrotoxic drugs (amphotericin B and colistin) raises concerns about patient safety. While the study focuses on in vitro efficacy, clinical translation would require careful consideration of toxicity profiles.
- Sub-MIC evaluation: While sub-MIC evaluations were performed, the paper notes that they showed no significantly different interactions for Aspergillus and Rhizopus species.
- Future Directions: The authors suggest that this study is a proof of concept, stimulating research into drugs targeting bacterial membranes for antifungal applications. Further investigation into the mechanisms behind the observed synergy and the clinical applicability of this combination, especially for Candida infections, is warranted.
Summary updated